Adam Robertson
Chief Scientific Officer Hemispherian
Seminars
Wednesday 2nd December 2026
Insights Exchange – How Can We Better Predict Clinical Success Before the Clinic?
11:40 am
- Which preclinical endpoints, biomarkers, and model characteristics are most consistently associated with successful clinical outcomes?
- How can organisations use clinical observations, imaging, and translational data to improve confidence in model-derived decisions and reduce late-stage risk?
- What are the most common reasons promising preclinical programmes fail in patients, and how can model strategies be refined to improve predictability?
- Audience Q&As
Wednesday 2nd December 2026
Evidence – Improving Confidence in Glioblastoma Development by Understanding What Truly Predicts Clinical Success
10:30 am
- Exploring why glioblastoma programmes continue to fail despite apparently encouraging preclinical data and examining the differences between marginal and clinically meaningful efficacy signals
- Evaluating the predictive value of orthotopic and translational tumour models to better understand which preclinical outcomes are most strongly associated with clinical success
- Applying lessons learned from glioblastoma development programmes to improve candidate selection, strengthen translational confidence, and avoid progression decisions based on weak or misleading data
